Aqua Bio Technology — Capital/Financing Update 2026

Mar 20, 2026

Aqua Bio Technology ASA: Preliminary results of the Subsequent Offering

Aqua Bio Technology ASA: Preliminary results of the Subsequent Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR

INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED

STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR

DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER

OF ANY OF THE SECURITIES DESCRIBED HEREIN

Reference is made to the stock exchange announcement by Aqua Bio Technology

ASA ("ABTEC" or the "Company") on 12 March 2026 regarding the start of the

subscription period in a subsequent offering of up to 800,000 new shares (the

"Offer Shares"), each at a subscription price of NOK 5.00 (the "Subsequent

Offering").

The Subscription Period expired yesterday, 19 March 2026, at 16:30 hours

(CET). The Company has been informed by our settlement agent that at the end

of the Subscription Period, and based on a preliminary count, valid

subscriptions had been received for a total of 388,240 Offer Shares.

The final result of the Subsequent Offering is expected to be announced by the

Company on or about 23 March 2026. Investors that are allocated Offer Shares

can access information on the number of Offer Shares allocated through VPS on

or about 23 March 2026. Further announcements in respect of the Subsequent

Offering and the Offer Shares will be made in due course.

The due date for payment of the Offer Shares is on 25 March 2026. Subject to

due payment of the Offer Shares by the subscribers, the share capital increase

relating to the Subsequent Offering will be registered with the Norwegian

Register of Business Enterprises, and the Offer Shares will thereafter be

delivered to the VPS accounts of the allocated subscribers on or about 8 April

2026. The Offer Shares will be delivered as listed and tradable shares. First

day of trading of the Offer Shares on Euronext Expand is expected on or about

8 April 2026. A separate announcement will be made when the share capital

increase has been registered.

IMPORTANT INFORMATION

This announcement is not an offer to sell or a solicitation of offers to

purchase or subscribe for shares. Copies of this announcement may not be sent

to jurisdictions, or distributed in or sent from jurisdictions, in which this

is barred or prohibited by law. The information contained herein shall not

constitute an offer to sell or the solicitation of an offer to buy, in any

jurisdiction in which such offer or solicitation would be unlawful absent

registration, or an exemption from registration or qualification under the

securities laws of any jurisdiction.

This document is not for publication or distribution in, directly or

indirectly, Australia, Canada, Japan, Hong Kong, South Africa or the United

States or any other jurisdiction in which such release, publication or

distribution would be unlawful, and it does not constitute an offer or

invitation to subscribe for or purchase any securities in such countries or in

any other jurisdiction. In particular, the document and the information

contained herein should not be distributed or otherwise transmitted into the

United States or to publications with a general circulation in the United

States of America.

This announcement is not an offer for sale of securities in the United States.

Securities may not be offered or sold in the United States absent registration

with the United States Securities and Exchange Commission or an exemption from

registration under the U.S. Securities Act of 1933, as amended (the

"Securities Act"). The Company does not intend to register any part of the

offering in the United States or to conduct a public offering in the United

States of the shares to which this document relates. This announcement is for

information purposes only and is not to be relied upon in substitution for the

exercise of independent judgment. It is not intended as investment advice and

under no circumstances is it to be used or considered as an offer to sell, or

a solicitation of an offer to buy any securities or a recommendation to buy or

sell any securities of the Company.

This announcement and any materials distributed in connection with this

announcement may contain certain forward-looking statements. By their nature,

forward-looking statements involve risk and uncertainty because they reflect

current expectations and assumptions as to future events and circumstances

that may not prove accurate. A number of material factors could cause actual

results and developments to differ materially from those expressed or implied

by these forward-looking statements.

The Company expressly disclaims any obligation or undertaking to update,

review or revise any statement contained in this announcement whether as a

result of new information, future developments or otherwise.

Contacts

Kristian Flaten

CEO & CFO

Aqua Bio Technology ASA

Phone: +47 9509 2322

Email: kf@aquabiotech.no

About Us

Aqua Bio Technology ASA (ABTEC) is a technology and distribution group in

skincare and nonfood. The group has distribution towards B2C and B2B, and

offers freight, customs, and logistics services. The group also develops

sustainable biotechnology for use in skincare products. Aqua Bio Technology is

listed on Euronext Expand Oslo.

This notice is published by Kristian Flaten on the listed date and time.

This information has been submitted pursuant to the Securities Trading Act §

5-12 and MAR. The information was submitted for publication, through the

agency of the contact persons set out above, at 2026-03-20 15:20 CET.